z-logo
open-access-imgOpen Access
A COMPARATIVE CLINICAL STUDY TO EVALUATE THE EFFICACY OF KANJIKADI GHRITA AND AMRUTADI GHRITA SNEHAPANA FOR VIRECHANA IN AMAVATA WITH SPECIAL REFERENCE TO RHEUMATOID ARTHRITIS
Author(s) -
J H Kavya,
Rajesh Sugur,
Doddabasayya Doddabasayya
Publication year - 2021
Publication title -
international ayurvedic medical journal
Language(s) - English
Resource type - Journals
ISSN - 2320-5091
DOI - 10.46607/iamj0909112021
Subject(s) - medicine , rheumatoid arthritis , clinical study , surgery
Amavata is a Vata and Kapha Pradhana Vyadhi caused due to Viruddha Ahara and Vihara resulting in Mandagni, leading to the formation of Ama. Ama with the influence of Vata Dosha circulates all over the body and gets lodged in Shleshma Sthana in Sandhi Pradesha, resulting in the manifestation of Amavata. Snehapana is a mandatory Poorvakarma before Shodhana. Snehapana does the Uthklesha of Doshas before Shodhana, without which proper achievement of Shuddhi is not possible. Snehapana and Virechana are the main lines of treatment for Amavata. To evaluate the better result, here for Snehapana Kanjakadi Ghrita & Amruthadi Ghrita were taken before Virechana which is then compared and analysed statistically. A minimum of 40 patients, fulfilling the diagnostic and inclusion criteria of Amavata according to Ayurveda classics and based on criteria fixed by the American Rheumatology Association (ARA) in 1988 criteria will be selected and randomly assigned into 2 groups, i.e. Group A and Group B consisting minimum of 20 patients in each group. Comparative analysis of the overall effect of the treatments in both groups was done statistically with the Unpaired T-Test. The test shows that the treatment is statistically not significant in Group A when compared to Group B. Overall result of Group A is 25.08% and the overall result of Group B is 31.07%.Keywords: Amavata, Kanjikadi Ghrita, Amritadi Ghrita, Snehapana, Virechana

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here